Substance / Medication

Streptomycin

Overview

Active Ingredient
streptomycin
RxNorm CUI
10109

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Epidemiology of streptomycin resistant Salmonella from humans and animals in Ethiopia: A systematic review and meta-analysis.
Mengistu Getachew, Dejenu Getiye, Tesema Cheru et al. · PLoS One · 2020
PMID: 33332438Meta-AnalysisFull text (PMC)
Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review.
Tanywe Asahngwa, Fernandez Ritin S · JBI Database System Rev Implement Rep · 2017
PMID: 28085731Meta-Analysis
Molecular analysis of the rpsL gene for rapid detection of streptomycin-resistant Mycobacterium tuberculosis: a meta-analysis.
He Jing, Zhu Baosheng, Yang Zhaojie et al. · Scand J Infect Dis · 2014
PMID: 24934990Meta-Analysis
Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review.
Vouking Marius Zambou, Tamo Violette Claire, Tadenfok Carine Nouboudem · Pan Afr Med J · 2013
PMID: 24396561Meta-AnalysisFull text (PMC)
Long term streptomycin toxicity in the treatment of Buruli Ulcer: follow-up of participants in the BURULICO drug trial.
Klis Sandor, Stienstra Ymkje, Phillips Richard O et al. · PLoS Negl Trop Dis · 2014
PMID: 24625583RCTFull text (PMC)
Doxycycline plus streptomycin versus ciprofloxacin plus rifampicin in spinal brucellosis [ISRCTN31053647].
Alp Emine, Koc Rahmi Kemal, Durak Ahmet Candan et al. · BMC Infect Dis · 2006
PMID: 16606473RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Streptomycin (substance)
SNOMED CT
387223008
UMLS CUI
C0038425
RxNorm CUI
10109

Clinical Data

This intervention maps to 12 entities in the Healos knowledge graph.

12
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.